4-HO-EPT

4-HO-EPT Summary

IUPAC Name: 3-{2-[Ethyl(propyl)amino]ethyl}-1H-indol-4-ol

Molecular Weight: 246.348

Formula: C15H22N2O

InChI: InChI=1S/C15H22N2O/c1-3-9-17(4-2)10-8-12-11-16-13-6-5-7-14(18)15(12)13/h5-7,11,16,18H,3-4,8-10H2,1-2H3

InChI Key: JQELEPKHBXEAHR-UHFFFAOYSA-N

SMILES: CCCN(CCc1c[nH]c2c1c(O)ccc2)CC

Links:

Similar Compounds:

4-HO-DPT
5-MEO-DALT
2-ME-DMT
DIPT
MIPT
MPT
MET
DPT
4-ACO-DMT
4-ACO-MET
4-ACO-DET
4-HO-MIPT
4-HO-MET
4-ACO-DPT
4-ACO-MIPT
4-HO-DET
4-HO-MCPT
4-HO-MPT
4-HO-MALT
4-MEO-MIPT
EPT
METHALLYLESCALINE
1P-LSD
MIPLA
1B-LSD
1P-ETH-LAD
1CP-LSD
ALD-52
ETH-LAD

References:

Brandt, SD; Kavanagh, PV; Westphal, F; Stratford, A; Elliott, SP; Hoang, K; Wallach, J; Halberstadt, AL. Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD). Drug Test. Analysis, 1 Sep 2016, 8 (9), 891–902. 1.8 MB. https://doi.org/10.1002/dta.1884

Brandt, SD; Kavanagh, PV; Twamley, B; Westphal, F; Elliott, SP; Wallach, J; Stratford, A; Klein, LM; McCorvy, JD; Nichols, DE; Halberstadt, AL. Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). Drug Test. Analysis, 1 Feb 2018, 10 (2), 310-322. 1.2 MB. https://doi.org/10.1002/dta.2222

Brandt, SD; Kavanagh, PV; Westphal, F; Stratford, A; Elliott, SP; Dowling, G; Wallach, J; Halberstadt, AL. Return of the lysergamides. Part V: Analytical and behavioural characterization of 1‐butanoyl‐d‐lysergic acid diethylamide (1B‐LSD). Drug Test. Analysis, 13 May 2019, n/a. 1.5 MB. https://doi.org/10.1002/dta.2613 #1P-LSD  LC,MS,NMR,IR,UV

EMCDDA. New drugs in Europe, 2015, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2016. 1.0 MB. #22

Halberstadt, AL; Geyer, MA. Effect of hallucinogens on unconditioned behavior. In Behavioral Neurobiology of Psychedelic Drugs; Halberstadt, AL; Vollenweider, FX; Nichols, DE, Eds., Springer, 1 Jan 2017; pp 159-199. 652 kB. https://doi.org/10.1007/7854_2016_466

Wagmann, L; Richter, LHJ; Kehl, T; Wack, F; Bergstrand, MP; Brandt, SD; Stratford, A; Maurer, HH; Meyer, MR. In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. Anal. Bioanal. Chem., 7 Jan 2019, n/a. 3.8 MB. https://doi.org/10.1007/s00216-018-1558-9 #11  MS

Grumann, C; Henkel, K; Stratford, A; Hermanns-Clausen, M; Passie, T; Brandt, SD; Auwärter, V. Validation of an LC-MS/MS method for the quantitative analysis of 1P-LSD and its tentative metabolite LSD in fortified urine and serum samples including stability tests for 1P-LSD under different storage conditions. J. Pharm. Biomed. Anal., 1 Sep 2019, 174 270–276. 726 kB. https://doi.org/10.1016/j.jpba.2019.05.062 #1P-LSD  LC,MS